Skip to contentC
Capricor Therapeutics, Inc.
C
CAPRCapricor Therapeutics, Inc. Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.12M$1.12Mderived−19.9% vs Q4 2014 Net Income-$3.35M-$3.35MderivedN/M vs Q4 2014 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Capricor Therapeutics, Inc. · CIK 1133869 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,284,930N/M Operating Cash Flowderived-$3,642,660N/M Free Cash Flowderived-$3,647,974N/M Margins · derivedOperating margin-292.4%−159.2 pt vs Q4 2014
Net margin-297.9%−160.3 pt vs Q4 2014
ended Dec 31, 2015 · filed Mar 30, 2016 · 90 d after period end